Abstract:ID 131403 Poster Board 569 Chemokine receptors 2 and 5 (CCR2 and CCR5, respectively) are highly homologous G-protein coupled receptors on the surface of select immune cells with distinct functions and endogenous agonists but with select shared antagonists. These chemokine receptors are promising targets for small molecule therapeutics in the treatment of various cancers and autoimmune diseases, despite only one currently approved therapeutic for CCR5. Rational design of future therapeutics relies on a structural understanding of the determinants of antagonist selectivity as high affinity targeting of only one receptor is often desired. Further complicating therapeutic development, antagonists of human CCR2 (hCCR2) are often inactive to mouse CCR2 (mCCR2). Here, through rationally-guided gain-of-function mutagenesis, we characterized the molecular determinants of CCR2/CCR5 and human/mouse antagonist selectivity. Binding poses for a panel of selective and dual-specific antagonists were generated through molecular docking. Using these poses, we hypothesized that a single bulky residue in TM2 of hCCR5 (Y892.63) and mCCR2 (Y1142.63) dictates selectivity by obstructing binding of the minor pocket-targeting orthosteric antagonists with large substituents. By contrast, the corresponding S1012.63 of hCCR2 is permissive to the binding of such antagonists because it allows them to occupy space otherwise filled by tyrosine. To validate this hypothesis, we introduced a Y892.63S mutation into human CCR5 and tested the ability of a previously CCR2-selective antagonist cherney08a_22 to inhibit chemokine-induced suppression of forskolin-stimulated cAMP in HeLa cells expressing the mutant. Intracellular cAMP levels were measured with the BRET-based CAMYEL reporter. These experiments confirmed that indeed the CCR5(Y892.63S) mutant became sensitive to cherney08a_22 . We also demonstrated how the same residue could impart selectivity against human CCR5 and mouse CCR2 to antagonists with a medium-size (acetamide) substituent. An alternative hypothesis was assessed for CCR2-selective antagonists predicted to bind towards TM5 and the major pocket. Selectivity for these hCCR2 antagonists was suspected to be conveyed by residues F1093.33, S18045.52, or I1985.42 of human CCR5, which are distinct from their CCR2 counterparts. However, the introduction of CCR2-mimicking F1093.33H and S18045.52P mutations in hCCR5 was not sufficient to produce sensitivity to major pocket-targeting CCR2-selective antagonist PF-4136309 . We therefore concluded that its selectivity mechanism is due to the hCCR2 residue R2065.42 which is I1985.42 in hCCR5. Our findings provide a better framework for the rational development of selective and dual-affinity antagonists for CCR2 and CCR5 to overcome past deficiencies in design of potent and selective inhibitors.

Non-selective antagonists acting at a stable cell-cell interface have the potential to induce signaling

Molecular Determinants for Ligand Selectivity of the Cell-Free Synthesized Human Endothelin B Receptor

Achieving signalling selectivity of ligands for the corticotropin-releasing factor type 1 receptor by modifying the agonist's signalling domain.

Non-Antigenic Modulation of Antigen Receptor (TCR) Cβ-FG Loop Modulates Signalling: Implications of External Factors Influencing T-Cell Responses

Bispecific Aptamer Induced Artificial Protein-Pairing: A Strategy for Selective Inhibition of Receptor Function.

Essential Dynamics of CB Receptor-Agonist Complexes: Implications for Signalling Bias

Molecular mechanism of biased signaling in a prototypical G protein–coupled receptor

Functionally selective dopamine D1 receptor endocytosis and signaling by catechol and non-catechol agonists

Allosterism in the adenosine A2A and cannabinoid CB2 heteromer

The beta 2 adrenergic receptor cross-linked interactome identifies 14-3-3 proteins as regulating the availability of signaling-competent receptors

Multiple Ligand-Specific Conformations of the Β2-Adrenergic Receptor

Structural Insights into CB1 Receptor Biased Signaling

Pleiotropy enables specific and accurate signaling in the presence of ligand cross talk

Intracellular pocket conformations determine signaling through the μ opioid receptor

Advances in Receptor Conformation Research: the Quest for Functionally Selective Conformations Focusing on the Β2-Adrenoceptor.

Molecular Mechanisms of Antagonist Selectivity Against CCR2 and CCR5

Molecular determinants of antagonist interactions with chemokine receptors CCR2 and CCR5

A non-canonical mechanism of GPCR activation

A quantitative view of strategies to engineer cell-selective ligand binding

Cannabinoid Receptor Signaling is Dependent on Sub-Cellular Location

Allosteric Coupling of Drug Binding and Intracellular Signaling in the A2A Adenosine Receptor